|
Dr. Harborth is Associate Director, RNAi Research at Cequent Pharmaceuticals. Prior to Cequent, Dr. Harborth was Senior Scientist at Alnylam Pharmaceuticals Inc. where he was responsible for research and development of therapeutics based on RNA interference (RNAi). In May 2001, Dr. Harborth and colleagues at Max Planck Institute for Biophysical Chemistry published a paper in Nature demonstrating that short double-stranded RNA sequences (known as small interfering RNAs, or siRNAs) effectively shut down protein production in mammalian cells, for the first time. At Alnylam, he extended the research and was successful in demonstrating that RNAi works in vivo (mice and non-human primates). These results were again published in Nature in 2004 and 2006, respectively. He received his venia legendi (habilitation) and a PhD in biochemistry summa cum laude from Georg-August University of Göttingen, Germany. | 